Bioventus Inc. reported $129.5 million in worldwide revenue in its first quarter of 2024 financial results, an 8.7% increase compared with its reported revenue in the first quarter of 2023, according to a company press release.
The company also reported a 15.3% revenue increase on an organic basis, as well as a net loss from continuing operations of $6 million, a significant decrease compared with a net loss from continuing operations of $100 million in the prior year period. The company reported adjusted earnings before interest, taxes, depreciation and amortization of $22.6 million, a 33.5%